|
Abstract To study the clinical value of E6/E7 mRNA detection of high risk HPV for screening cervical lesions of pregnant women and puerpera. Methods: 64 patients with cervical disease were selected as research objects from June 2018 to June 2019. Based on their results of the cervical pathology, the E6/E7 mRNA of HPV detection and HPV DNA detection were performed for patients with different grades of cervical lesions, and the detection efficiency were compared between the two detections. Results: The positive rate of E6/E7 mRNA of HPV detection of patients with chronic inflammation, CIN Ⅰ, CIN Ⅱ, CIN Ⅲ had no significant different from that of HPV DNA detection. The total positive rate of E6/E7 mRNA of HPV detection was 53.1%, which had no significant different from that (59.4%) of HPV DNA detection (all P>0.05). The detection consistency by the two detections for patients with chronic inflammation, CIN, and cervical cancer were 80.8%, 85.2%, and 81.8%, respectively, and their κvalues were 0.42, 0.56 and 0.81, respectively. The specificity by HPV DNA detection was 60.2%, which was significant lower than that (85.2%) by E6/E7 mRNA of HPV detection (P<0.05). There were no significant different in the sensitivity, the positive predictive value, and the negative predictive value between HPV DNA detection and E6/E7m RNA of HPV detection (P>0.05). Conclusion: Compared with HPV NDA detection, E6/E7 mRNA of HPV detection can better predict the progress of cervical lesions of pregnant women and puerpera, especially for women with high-grade cervical lesions.
|
|
|
|
|
|
